Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy

Prentice, A. G., Barnes, Rosemary Ann, Rogers, T. R. F., Cohen, J., Denning, D. W., Evans, E. G. V., Hay, R. J., Speller, D. C. E., Warnock, D. W. and Warren, R. E. 1997. Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy. Journal of Antimicrobial Chemotherapy 40 (6) , pp. 779-788. 10.1093/jac/40.6.779

Full text not available from this repository.

Abstract

The treatment of deep fungal infection in haematological malignancy remains controversial due to the limited number of antifungal agents available and problems over their spectrum and dose-limiting side-effects. Difficulties in diagnosis mean that most treatments are begun empirically; amphotericin B remains the drug of choice. Emerging resistance may limit the usefulness of fluconazole and other azoles in some areas. Lipid preparations of amphotericin B have reduced the toxicity of this agent, but some issues of dosage and efficacy remain. Adjunctive treatments aimed at augmenting the host response to infection may have a role to play in deep fungal infection.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Oxford University Press
ISSN:	1460-2091
Last Modified:	04 Jun 2017 04:20
URI:	https://orca.cardiff.ac.uk/id/eprint/37074

Citation Data

Cited 25 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item